Bioabsorbable blend for temporary scaffolding of the blood vessel wall
Inventors
Kim, Hyung Il • Ishihara, Kazuhiko
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8575229-B2
Publication Date
2013-11-05
Expiration Date
Abstract
A bioabsorbable blend comprising poly(L-lactide) (PLLA) and a phosphorylcholine group-containing copolymer (PPCP) capable of enduring the mechanical strength of blood vessel walls and applicable for fabricating cardiovascular devices was developed. The blend acts as a scaffold to support blood vessel walls during vascular healing and undergoes biodegradation in vivo after vascular healing is complete. Furthermore, the blend can prevent the formation and adsorption of thrombi.
Core Innovation
The invention provides a bioabsorbable blend comprising poly(L-lactide) (PLLA) and a phosphorylcholine group-containing copolymer (PPCP). The blend uses PPCP to create a phosphorylcholine-rich, blood-compatible surface while retaining mechanical strength from PLLA. The document links the blend composition to the resulting surface character and to biodegradation after vascular healing.
The phosphorylcholine group-containing copolymer (PPCP) includes MPC-based copolymerization, with an example identified as PMB30W. The disclosure characterizes the blend surface using X-ray photoelectron spectroscopy (XPS) and reports evidence such as a P/C surface ratio to support a phosphorylcholine-rich surface. The phosphorylcholine-rich surface suppresses platelet adhesion and thrombus formation.
In the context of temporary blood-vessel scaffolding, the blend is biodegradable after vascular healing. The document reports mechanical and degradation-related evaluation and identifies cardiovascular devices, including biodegradable stents formed from tube/cast film fabrication and laser cutting, in which the bioabsorbable blend is used.
Claims Coverage
The independent claim covers a bioabsorbable blend comprising PLLA and a phosphorylcholine group-containing copolymer (PPCP). Additional dependent claims further specify the PPCP preparation and selection and narrow the use to cardiovascular devices, including stents formed from a tube or from a cast film.
Bioabsorbable blend of PLLA and PPCP
A bioabsorbable blend comprising PLLA (poly(L-lactide)) and a phosphorylcholine group-containing copolymer (PPCP).
PPCP content within a specified weight range
The blend includes PPCP at 0.5 wt% to 8 wt% of the total blend weight.
PPCP prepared by MPC-based copolymerization
PPCP is prepared by copolymerizing a 2-methacryloyloxethyl phosphoroylcholine (MPC) unit with a selected comonomer from a listed group, or a combination of them.
PPCP selected from specified PPCP polymer compositions
The PPCP component is selected from a specified group of listed PPCP polymer compositions.
Cardiovascular device for treating cardiovascular disease using the blend
A cardiovascular device for treating a cardiovascular disease includes the bioabsorbable blend.
Stent made by processing a tube of the bioabsorbable blend
The cardiovascular device is a stent made by processing a tube of a bioabsorbable blend.
Overall, the claim coverage centers on a bioabsorbable PLLA/PPCP blend and further narrows the inventive composition through PPCP content, MPC-based copolymerization-defined PPCP preparation, and PPCP selection from specified polymer compositions. It additionally narrows the end-use to cardiovascular devices including stents, with at least one route specified as processing a tube of the bioabsorbable blend.
Stated Advantages
Provides a phosphorylcholine-rich, blood-compatible surface.
Suppresses platelet adhesion and thrombus formation.
Maintains mechanical strength from PLLA while enabling biodegradation after vascular healing.
Documented Applications
Temporary blood-vessel scaffolding using a biodegradable PLLA/PPCP blend.
Biodegradable stents, including stent fabrication using tube/cast film fabrication and laser cutting.
Cardiovascular devices for treating cardiovascular disease.
Interested in licensing this patent?